Pharmaceuticals, Biotechnology & Life Sciences

Vaxcyte’s $11B equity‑debt offering fuels its vaccine innovation push—boosting R&D and global health impact with robust financial backing.

Vanda Pharmaceuticals’ 13G/A filing shows Millennium entities hold ~7% of shares, yet no control intent—still focused on CNS drug development.

Argenx’s celiac win vs. Sjögren’s setback: how a Phase II breakthrough and a Phase III failure reshape its stock, valuation, and investor outlook.

Phio Pharmaceuticals advances cancer immunotherapy, tackling R&D and market volatility while targeting personalized treatments—discover its biotech prospects.

Ocugen’s recent Form 144 filing details the insider sale of 400k+ shares, highlighting its biotech focus and stock movement for investors.

Fate Therapeutics, a San Diego biotech, pioneers stem‑cell therapies for tissue repair, driving regenerative medicine breakthroughs and offering new hope for patients.

Arcturus Therapeutics’ RNA‑therapy ambitions clash with sharp stock swings, a negative P/E, and complex Federated Hermes ownership, raising investor concerns.

Discover how Corcept Therapeutics’ cortisol‑modulating drug targets GR‑II to treat metabolic and psychiatric disorders, driving strong stock growth and future healthcare innovation.

Explore how Hyperliquid Strategies, Inc. navigated the 2026 crypto crash, leveraged positions, and regulatory shifts to stay resilient in the volatile market.

CRISPR Therapeutics AG faces a pivotal AHA presentation that could unlock its gene‑editing breakthrough in cardiovascular care, offering investors a high‑potential but volatile opportunity.